-
Mashup Score: 2Monoclonal antibody cocktail cut COVID-19 hospitalization, death by 70% in outpatient setting - 3 year(s) ago
A cocktail of two monoclonal antibodies — casirivimab and imdevimab — significantly reduced the risk for hospitalization or death in nonhospitalized patients with COVID-19, according to results of a phase 3 pivotal trial.Casirivimab with imdevimab (REGEN-COV, Regenerson) also shortened symptom duration and reduced viral load, researchers reported during a breaking news session at the
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 2Monoclonal antibody cocktail cut COVID-19 hospitalization, death by 70% in outpatient setting - 3 year(s) ago
A cocktail of two monoclonal antibodies — casirivimab and imdevimab — significantly reduced the risk for hospitalization or death in nonhospitalized patients with COVID-19, according to results of a phase 3 pivotal trial.Casirivimab with imdevimab (REGEN-COV, Regenerson) also shortened symptom duration and reduced viral load, researchers reported during a breaking news session at the
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
Presented at #ATS2021: Monoclonal antibody cocktail (REGEN-COV) of #casirivimab plus #imdevimab significantly hospitalization, death, symptom duration and viral load in non-hospitalized patients with #COVID19 @InfectDisNews https://t.co/yEyp8CNbVn
-
Presented at #ATS2021: Monoclonal antibody cocktail (REGEN-COV) of #casirivimab plus #imdevimab significantly hospitalization, death, symptom duration and viral load in non-hospitalized patients with #COVID19 @InfectDisNews https://t.co/PO2cB2x258
-
-
Mashup Score: 25COVID-19 Guideline, Part 1: Treatment and Management - 3 year(s) ago
COVID-19 is a pandemic with a rapidly increasing incidence of infections and deaths. Many pharmacologic therapies are being used or considered for treatment. Given the rapidity of emerging literature, IDSA felt the need to develop living, frequently updated evidence-based guidelines to support patients, clinicians and other health-care professionals in their decisions about treatment and…
Source: www.idsociety.orgCategories: Infectious Disease, Latest HeadlinesTweet-
IDSA has released new guideline recommendations on the use of #bamlanivimab among hospitalized patients and #casirivimab/#imdevimab among ambulatory patients for the Treatment & Management of Patients with COVID-19. #COVID19Guidelines 📄https://t.co/SK6zyOJKtO https://t.co/jxE6rLy67l
-
-
Mashup Score: 3
The FDA granted emergency use authorization for the monoclonal antibodies casirivimab and imdevimab to be administered together intravenously for the treatment of mild to moderate COVID-19.According to a press release, this EUA pertains to adults and children aged 12 years and older with positive SARS-CoV-2 viral test results who weigh 88 pounds or more and are at high risk for progressing to
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
The @US_FDA granted emergency use authorization for the @Regeneron monoclonal antibodies #casirivimab & #imdevimab to be administered together intravenously for treatment of mild to moderate #COVID-19 https://t.co/bQznLW7CYf #coronavirus #COVID19 #coronaviruspandemic #medtwitter https://t.co/EIcS4wTsff
-
-
Mashup Score: 14Coronavirus Treatment and Prevention With Monoclonal Antibodies - 3 year(s) ago
Neutralizing monoclonal antibodies (mAbs) may be a highly effective way to treat and prevent COVID-19 while waiting for a vaccine. Watch this video to find o…
Source: YouTubeCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
The FDA announced emergency use authorization for @Regeneron's combination #casirivimab and #imdevimab, for the treatment of mild- moderate #COVID19. Revisit our video explaining the production and rationale for #MAb treatment of #coronavirus https://t.co/03noQf7fBO
-
Presented at #ATS2021: Monoclonal antibody cocktail (REGEN-COV) of #casirivimab plus #imdevimab significantly hospitalization, death, symptom duration and viral load in non-hospitalized patients with #COVID19 @InfectDisNews https://t.co/2FkNau6qQK